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The transcription factorRUNX1 is frequentlymutated
in myelodysplastic syndrome and leukemia. RUNX1
mutations can be early events, creating preleukemic
stem cells that expand in the bone marrow. Here
we show, counterintuitively, that Runx1-deficient
hematopoietic stem and progenitor cells (HSPCs)
have a slow growth, low biosynthetic, small cell
phenotype and markedly reduced ribosome biogen-
esis (Ribi). The reduced Ribi involved decreased
levels of rRNA and many mRNAs encoding ribosome
proteins. Runx1 appears to directly regulate Ribi;
Runx1 is enriched on the promoters of genes encod-
ing ribosome proteins and binds the rDNA repeats.
Runx1-deficient HSPCs have lower p53 levels,
reduced apoptosis, an attenuated unfolded protein
response, and accordingly are resistant to genotoxic
and ER stress. The low biosynthetic activity and cor-
responding stress resistance provides a selective
advantage to Runx1-deficient HSPCs, allowing
them to expand in the bone marrow and outcompete
normal HSPCs.
INTRODUCTION
Myelodysplastic syndrome (MDS) and acute myelogenous leu-
kemia (AML) begin with the acquisition of a driver mutation that
generates a preleukemic stem cell (pre-LSC) (Pandolfi et al.,
2013). The pre-LSC is self-renewing and capable of competing
with normal hematopoietic stem cells (HSCs) to ensure its sur-
vival and expansion in the bone marrow. Additional mutations
gradually accumulate in the pre-LSC and its downstream prog-
eny, giving rise to MDS or AML (Welch et al., 2012). Early muta-
tions in the leukemogenic process often occur in genes encoding
chromatin regulators such as TET2, DNMT3A, IDH2, and ASXL1
(Welch et al., 2012; Xie et al., 2014). These genes mediateCprocesses such as DNA methylation, histone modification, or
chromatin looping, altering the epigenetic ‘‘landscape’’ of the
pre-LSC (Corces-Zimmerman et al., 2014; Jan et al., 2012;
Shlush et al., 2014). Mutations that activate signal transduction
pathways, such as internal duplication of FLT3 are also common
in AML, but most often occur as later events in downstream pro-
genitor populations (Corces-Zimmerman et al., 2014).
RUNX1 is a DNA binding transcription factor that is mutated
in de novo and therapy-related AML, MDS, chronic myelo-
monocytic leukemia, acute lymphocytic leukemia, and in the
autosomal dominant pre-leukemia syndrome familial platelet
disorder with predisposition to acute myeloid leukemia (FPD/
AML) (Mangan and Speck, 2011). In mice, loss-of-function
(LOF) Runx1 mutations cause defects in lymphocyte and mega-
karyocytic development, and alterations in hematopoietic stem
and progenitor cells (HSPCs) that include an increase in the num-
ber of committed erythroid/myeloid progenitors and expansion
of the lineage-negative (L) Sca1+ Kit+ (LSK) population in the
bone marrow (Cai et al., 2011; Growney et al., 2005; Ichikawa
et al., 2004). Runx1 deficiency has only a modest adverse effect
on the number of functional long-term repopulating hematopoi-
etic stem cells (LT-HSCs), reducing their frequency in the bone
marrow by 3-fold at most, without affecting their self-renewal
properties (Cai et al., 2011; Jacob et al., 2010). LOF RUNX1mu-
tationsmay also confer increased resistance to genotoxic stress,
because several small-scale studies of MDS/AML patients who
were previously exposed to radiation or treated with alkylating
agents revealed a high incidence (40%) of somatic single
nucleotide variants or insertion/deletion mutations in RUNX1,
as compared to the overall 6%–10% of MDS patients with LOF
RUNX1mutations (Bejar et al., 2011; Haferlach et al., 2014; Har-
ada et al., 2003; Walter et al., 2013; Zharlyganova et al., 2008).
The higher association of RUNX1 mutations with exposure to
genotoxic agents suggests two possibilities: either RUNX1 mu-
tations are preferentially induced by these agents, or more likely,
that pre-existing RUNX1mutations conferred a selective advan-
tage to pre-LSCs exposed to these agents. RUNX1 mutations
can be early or later events in the progression of MDS and
AML (Jan et al., 2012; Welch et al., 2012). That they can be early
events is demonstrated unequivocally by the observation thatell Stem Cell 17, 165–177, August 6, 2015 ª2015 Elsevier Inc. 165
FPD/AML patients who harbor germline mutations in RUNX1
have an 35% lifetime risk of developing MDS/AML (Ganly
et al., 2004; Michaud et al., 2002; Song et al., 1999).
Although it has been demonstrated that mutations that occur
in pre-LSCs cause them to selectively expand in the bone
marrow (Busque et al., 2012; Xie et al., 2014), the mechanisms
underlying this phenomenon are not well understood. Here we
aimed to elucidate the molecular mechanisms by which LOF
RUNX1 mutations generate an expanded population of HSPCs.
Counterintuitively, we find that Runx1 deficiency in HSPCs re-
sults in a slow growth, low biosynthetic, small cell phenotype,
accompanied by markedly decreased ribosome biogenesis
(Ribi). Furthermore, Runx1-deficient HSPCs have lower levels
of p53 and an attenuated unfolded protein response and are
less apoptotic following exposure to genotoxic stress. These
observations lead to a model whereby LOF RUNX1 mutations
generate stress-resistant HSPCs that are able to perdure and
expand by virtue of their slow growth properties and decreased
rates of apoptosis as compared to normal HSPCs.
RESULTS
We previously demonstrated that Runx1-deficient murine
HSPCs have a decreased percentage of apoptotic cells (Cai
et al., 2011). To determine if Runx1 deficiency also protects
against radiation-induced apoptosis, we generated hematopoi-
etic-specific LOF Runx1 alleles with Vav1-Cre (Cai et al., 2011).
We irradiated control Runx1f/f (f/f) and Runx1f/f; Vav1-Cre (D/D)
mice and measured the percentage of apoptotic HSPCs 24 hr
later. HSPCs were analyzed using CD34 and Flt3 markers,
because we previously showed that CD48 and CD150 are dysre-
gulated on Runx1-deficient HSPCs (Cai et al., 2011). Staining for
Kit was not performed as its levels decrease following irradiation
(Simonnet et al., 2009). A smaller percentage of irradiated D/D
CD34 Flt3 LS (long-term repopulating HSCs) and CD34+
Flt3 LS cells (short-term HSCs) were Annexin V+ compared
to f/f HSCs (Figures 1A and 1B). Runx1 deficiency did not, how-
ever, reduce the sensitivity of CD34+ Flt3+ LS cells (multipotent
progenitors, MPPs) to radiation. Because reduced apoptosis
and other properties to be discussed later were common to
both CD34+ Flt3 and CD34 Flt3 LSK cells, these two popula-
tions were combined (Flt3 LSK cells or Flt3 LS cells in exper-
iments involving radiation or R24 hr of in vitro culture) in most
experiments.
To determine if Runx1 deficiency provides a selective advan-
tage to HSCs following radiation exposure, we mixed bone
marrow (BM) cells from f/f or D/Dmice with wild-type competitor
BM (+/+) at a 3:4 ratio, and either transplanted the cells directly
into lethally irradiated (9Gy) recipient mice, or first subjected
the cells to a low level of irradiation (2 Gy) prior to transplantation
(Figure 1C). If donor HSCs are less sensitive to radiation than +/+
competitor HSCs, the ratio of donor to +/+ competitor cells
should increase following irradiation. The ratio of non-irradiated
f/f donor to +/+ competitor cells in peripheral blood (PB), total
BM, Mac1+ BM cells, and LSK BM cells was the same as the
input 3:4 ratio, and not altered by radiation (Figure 1D). In
contrast, D/D LSK cells expanded in the BM relative to +/+
competitor cells (p% 0.002) (Figure 1E), as previously reported
(Cai et al., 2011; Chen et al., 2009; Growney et al., 2005; Ichikawa166 Cell Stem Cell 17, 165–177, August 6, 2015 ª2015 Elsevier Inc.et al., 2004; Jacob et al., 2010; Motoda et al., 2007). Radiation
further increased the percentage of D/D donor-derived total
BM and BM LSK cells relative to non-irradiated D/D cells, and
there was a trend toward increased BM Mac1+ cells (Figure 1E).
Therefore, Runx1-deficient HSCs have a selective advantage
over normal HSCs that is accentuated by irradiation.
LOF RUNX1 mutations in AML are associated with refractory
disease and inferior event-free, relapse-free, and overall survival,
presumably due to chemotherapy resistance (Gaidzik et al.,
2011; Tang et al., 2009). To determine if Runx1 deficiency
protects HSCs from chemotherapeutic agents, mice were
treated for 5 days with arabinofuranosyl cytidine (Ara-C) and
apoptosis analyzed. Ara-C treatment increased the percentage
of apoptotic CD34 Flt3 LS cells of both genotypes, but the
percentage of Annexin V+ cells was lower in D/D than in f/f
HSCs (Figures 1F–1H).
The expansion and decreased apoptosis of Runx1-deficient
HSCs in the absence of induced stress suggests that they are
also resistant to endogenous stress. Tunicamycin induces ER
stress by blocking N-linked glycosylation, which causes mis-
folded proteins to accumulate in the ER and trigger the unfolded
protein response (UPR). Treatment of mice with tunicamycin
induced apoptosis of both f/f and D/D Flt3 LSK cells, but to a
much lesser extent in D/D cells (Figure 1I). The expression of
several UPR response genes was induced following irradiation,
but activation of Atf6, Ddit3 (CHOP), and Xbp1 was significantly
attenuated inD/D Flt3 LS cells (Figure 1J). BecauseD/DHSPCs
have a slow growth phenotype and do not exhibit increased self-
renewal in serial transplant experiments (Cai et al., 2011), we
conclude that their expansion in the BM likely results from their
increased resistance to endogenous and genotoxic stress.
Runx1-Deficient HSCs Have Decreased Ribosome
Content
We noticed during the course of our analyses that D/D HSPCs
produced less forward scatter (FSC) than f/f HSCs, indicating
they are smaller in size. This was observed for D/D CD34
Flt3 LSK (LT-HSCs), CD34+ Flt3 LSK (ST-HSCs), and LKS
(progenitor) cells, although not for CD34+ Flt3+ LSK cells
(MPPs) (Figures 2A and 2B), which coincidentally had normal
levels of apoptosis (Figures 1A and 1B). D/D HSCs also had a
smaller diameter than f/f HSCs (Figure 1C). To determine if this
small cell phenotype was also relevant in humans, we analyzed
CD117+ CD34+ BM cells from two FPD/AML patients with het-
erozygous LOF RUNX1 mutations. CD117+ CD34+ cells from
these individuals also produced less FSC as compared to cells
from age-matched control patients analyzed in the clinic on the
same day, on the same cytometer (Figure 2D). Although the
available samples are too few to draw any firm conclusions,
the data suggest that human FPD/AML HSPCs are relatively
small. Murine HSPCs with a mono-allelic LOF Runx1 mutation
were not, however, smaller than wild-type HSCs (not shown).
Cell size is thus one of several aspects of Runx1 haploinsuffi-
ciency in mice that differs from the human FPD/AML phenotype
(Sun and Downing, 2004), because mouse and humans appear
to have different sensitivities to moderately reduced Runx1
dosage.
Cell size generally correlates with ribosome biogenesis (Ribi)
(Cook and Tyers, 2007); therefore, we measured the amount of
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Figure 1. Runx1 Deficiency Protects HSCs from Genotoxic Stress
(A) Apoptosis in phenotypic LT-HSCs (CD34 Flt3 LS), ST-HSCs (CD34+ Flt3 LS), andMPPs (CD34+ Flt3+ LS). Mice were irradiated and 24 hr later 7AAD cells
analyzed for Annexin V staining. f/f, Runx1f/f; D/D, Runx1f/f;Vav1-Cre; FMO, fluorescence minus one control.
(B) Summary of data in (A) (mean ± SD, n = 6–7 mice per genotype, unpaired two-tailed Student’s t test). 34, CD34; F, Flt3.
(C) In vivo competition experiment. 1.53 106 f/f orD/D donor BMcells weremixedwith 23 106wild-type competitor BMcells. The cells were exposed to 0 or 2Gy
radiation then transplanted into recipient mice. Peripheral blood (PB) and BM were analyzed 2 months post-irradiation.
(D) The percentage of f/f donor-derived cells [donor/(donor + competitor + residual host)] and +/+ competitor-derived cells [competitor/(donor + competitor +
residual host)] is plotted as a ratio of percentage donor/percentage competitor. The experiment was repeated three times, each time using one f/f and one D/D
donor. Plotted is a representative experiment (mean ± SD, n = 5–6 recipients, unpaired one-tailed Student’s t test).
(E) The percentage of D/D donor-derived cells divided by the percentage of +/+ competitor cells as in (D). There was a significant expansion in non-irradiatedD/D
BM Mac1+ (p% 0.03) and BM LSK cells (p% 0.03) compared to their non-irradiated f/f counterparts.
(F) Mice were injected for 5 consecutive days with vehicle (PBS) or 10 mg/kg Ara-C, and BM was analyzed on day 6.
(G) Scatter plots show gating for LS cells (Kit was not gated because its levels decreased following Ara-C treatment).
(H) Percentage of apoptotic CD34 Flt3 LS cells with or without Ara-C treatment (mean ± SD, n = 7–9 mice, unpaired two-tailed Student’s t test).
(I) Percentage of Annexin V+ Flt3 LSK cells 24 hr post intraperitoneal (i.p.) injection of 1 mg/kg tunicamycin (Tu) or vehicle into mice (mean ± SD, n = 4–7 mice,
p value determined by ANOVA; all values are significantly different from the comparator [#] by Dunnett’s multiple comparison test).
(J) Expression of UPR transcripts (qPCR) in Flt3 LS cells with and without 10 Gy irradiation (mean ± SD, n = 3–8 mice, unpaired two-tailed Student’s t test).
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Figure 2. Runx1-Deficient Pre-LSCs Have Decreased Ribosome Biogenesis
(A) Forward scatter analysis of progenitor and HSPC populations.
(B) Summary of data in (A) (mean ± SD, n = 10–12, unpaired two-tailed Student’s t test).
(C) Mean diameters of Flt3 LSK cells, indicated by black lines, p value was determined by unpaired two-tailed Student’s t test.
(D) Forward scatter analysis of CD117+ CD34+ BM cells from two FPD/AML patients and two unaffected controls. FPD/AML patient 1 and control 1 were age-
matched adults whose BM was analyzed on the same day on the same cytometer in the clinic. FPD/AML patient 2 and control 2 were age-matched children
analyzed together on a different day. Mean FSC values are indicated. The FPD/AML patients are heterozygous for a non-functional RUNX1 allele in which exons
2–6 are duplicated.
(E) Total RNA amount in 1,000 f/f and D/D LK cells (mean ± SD, n = 3–4, unpaired two-tailed Student’s t test).
(F) Ribosome profiling. Lysates from 4.5 3 106 f/f or D/D cells were lysed and centrifuged through a sucrose gradient.
(G) Glucose consumption of LSK cells. Cells were cultured in 25 mM glucose for 24 hr and the change in glucose concentration in the culture medium measured
(mean ± SD, n = 8, unpaired two-tailed Student’s t test).
(H) ATP levels in sorted cells (mean ± SD, n = 6, unpaired two-tailed Student’s t test).total RNA in Runx1-deficient cells, as the vast majority (>85%)
of cellular RNA comprises or encodes components of the
ribosome. Indeed, Runx1-deficient HSPCs (LKS+/, heretofore
designated LK) contained 50% less total RNA than f/f cells on
a per-cell basis (Figure 2E). We also examined ribosome compo-
sition by preparing lysates from equal numbers of f/f and D/D LK
cells, centrifuging the lysates through a sucrose gradient, and
recording the UV absorbance of individual fractions.D/D LK cells
had fewer ribosomes in all fractions, including polysomes, 80S
assembled ribosomes, and large and small ribosomal subunits168 Cell Stem Cell 17, 165–177, August 6, 2015 ª2015 Elsevier Inc.(Figure 2F). Analysis of three separate sucrose gradient experi-
ments showed no perturbation of the 60S/40S subunit ratio,
and therefore Ribi was decreased in a balancedmanner. Consis-
tent with the decreased Ribi, Runx1-deficient cells had a low
metabolic profile; D/D LSK cells consumed less glucose when
cultured in vitro (Figure 2G), and both LKS and Flt3 LSK cells
produced less ATP than their f/f counterparts (Figure 2H). Runx1
promotesG1 to S phase cell-cycle progression (Friedman, 2009),
and correspondingly Runx1-deficient HSPCs contain a higher
percentage of cells in G1 (Cai et al., 2011). Because decreased
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Figure 3. Ribosome Protein and rRNA Tran-
scripts Are Decreased in D/D HSCs
(A) Histogram of overall gene expression changes
in D/D versus f/f Flt3 LSK cells. Sequencing
libraries were prepared from Poly(A) selected RNA
from duplicate samples of 2 3 104 cells sorted
directly into Trizol, with added spike-in controls.
(B) Heatmap of changes in ribosome protein
mRNAs and rRNAs. Libraries for rRNA analysis
were prepared from total RNA.
(C) Relative expression of genes encoding struc-
tural components of ribosomes.
(D) Histogram of OP-Puro incorporation following
1 hour of in vivo labeling.
(E) Summary of OP-Puro incorporation (mean ±
SD, n = 7–8, unpaired two-tailed Student’s t test).
See also Table S1.Ribi also delays G1 to S phase progression (Donati et al., 2012),
decreased Ribi may underlie the effect of Runx1 deficiency on
the cell cycle.
We performed RNA-seq tomeasure the relative levels of RNAs
encoding or comprising structural components of the ribosome,
using spike-in controls to normalize the data according to cell
number. We made two separate sequencing libraries: one from
polyA-selected RNA to analyze mRNAs encoding ribosome pro-
teins, and one from total RNA to compare rRNA levels. In total,
4,248 genes were differentially expressed (FDR < 0.05). There
was an average 11% decrease in overall mRNA levels in D/D
Flt3 LSK cells (Figure 3A), and a slightly greater 13% decrease
in mRNA transcripts for ribosome proteins (Figures 3B and 3C).
Although an 11% versus 13% difference is small, it was signifi-
cant (p < 0.01, one-tailed t test), indicating that the expression
of ribosome protein genes (as compared to all genes) was pref-
erentially affected by Runx1 loss. The largest reduction was in
rRNA, which was lower by 51% in D/D HSCs (Figure 3C), similar
to the reduction in total RNA levels in LK cells (Figure 2E).
Decreased biosynthetic capacity should negatively affect
the rate of translation. We examined translation by measuring
the incorporation of the alkyne puromycin analog O-propargyl-Cell Stem Cell 17, 165–17puromycin (OP-Puro) into nascent pep-
tides following injection into mice, as
described by Signer et al. (Signer et al.,
2014). D/D Flt3 LSK cells incorporated
significantly less OP-Puro than f/f cells,
indicating that the overall rate of transla-
tion was decreased in D/D HSCs (Figures
3D and 3E).
Decreased Ribi Can Be Partially
Reversed by Activating mTOR
Signaling
The mTOR pathway is an important regu-
lator of cell growth, Ribi, and overall
translation. Activated mTOR phosphory-
lates 4EBP1, relieving its repression of
eIF4E, allowing Cap-dependent transla-
tion initiation (Figure 4A). mTOR also
phosphorylates ribosomal protein S6 ki-nase (S6K), which directly regulates Ribi by phosphorylating
the small ribosomal protein S6, and by inactivating several re-
pressors of rRNA and ribosome protein transcription (Huber
et al., 2011). The overall levels of S6, 4EBP1, tuberous sclerosis
complex 2 (TSC2), and actin were slightly decreased in D/D LK
and Flt3 LSK cells freshly isolated from the BM (Figure 4B).
Phosphorylated 4EBP1 (p-4EBP1) was lower relative to total
4EBP1 raising the possibility that tonic mTOR signaling was
slightly dampened. The p-S6 level varied in different experi-
ments; in some experiments it was elevated in D/D CD34+/
Flt3 LSK cells (Figure S1), and in other experiments p-S6 was
lower (Figure 4B). Although the activation status of tonic mTOR
signaling was somewhat equivocal, our interpretation is that it
is not greatly decreased and unlikely to account for the 50%
decrease in Ribi.
We examined mTOR signaling further by analyzing mTOR
pathway activation in response to hematopoietic cytokines.
Runx1 directly regulates several cytokine receptors including
MPL, the receptor for thrombopoietin (TPO), an important regu-
lator of HSC function (Cai et al., 2011; Heller et al., 2005; Kimura
et al., 1998; Solar et al., 1998). Therefore, we predicted that
Runx1-deficient HSPCs might be less responsive to mTOR7, August 6, 2015 ª2015 Elsevier Inc. 169
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Figure 4. mTOR Signaling in Runx1-Deficient HSPCs
(A) Summary of mTOR pathway. Blue indicates proteins or phosphorylation events that were examined by western blot.
(B) Western blot of mTOR pathway proteins in freshly isolated HSPCs (lysates from 20,000 cells/lane).
(C) Activation of the mTOR pathway as measured by phosphorylation of S6 in serum-starved cells stimulated with SCF or TPO at the indicated concentrations.
CK, cytokine.
(D) Western blot for p-S6 in lysates prepared from 20,000 Flt3 LSK cells 24 hr following i.p. injection of the PTEN inhibitor VO-OHpic trihydrate (PTENi).
(E) Left: qPCR for 45S rRNA in Flt3 LSK cells 24 hr following i.p. injection of vehicle or PTENi (mean ± SD, n = 3–5 mice). Right: apoptosis in Flt3 LSK cells
following injection of PTENi (mean ± SD, n = 3–6 mice). The p values determined by one-way ANOVA; values significantly different from the comparators (#) by
Dunnett’s multiple comparison test are indicated with asterisks.
See also Figure S1.activation by cytokines. We tested the response of D/D Flt3
LSK cells to TPO, and also to stem cell factor (SCF) to determine
if this was the case. The addition of 10 ng/ml TPO or SCF to
serum-starved f/f and D/D Flt3 LSK cells in vitro resulted in
S6 phosphorylation within 10 min (Figure 4C). Contrary to our
prediction, the mean fluorescence intensity (MFI) of p-S6 was
higher in D/D Flt3 LSK cells relative to f/f cells following TPO
or SCF stimulation. f/f and D/D Flt3 LSK cells also responded170 Cell Stem Cell 17, 165–177, August 6, 2015 ª2015 Elsevier Inc.to similar concentrations of TPO and SCF (Figure 4C). We
conclude that the mTOR pathway could be robustly activated
by TPO and SCF in D/D Flt3 LSK cells.
Activation of mTOR signaling can correct some of the prolifer-
ation, differentiation, and translation defects associated with
mutations in ribosome protein genes (Boultwood et al., 2013;
Payne et al., 2012). To determine whether activation of mTOR
signaling could reverse the decreased Ribi and apoptosis in
DBA
C
Figure 5. Runx1-Deficient HSPCs Do Not Undergo Increased Autophagy
(A) Relative mRNA levels for core (black labels) and pro-autophagy genes (green labels) in freshly isolated Flt3 LS cells without or 24 hr post-10-Gy radiation
(mean ± SD, n = 3–8, p value determined by one-way ANOVA, significantly different values were determined by Bonferroni’s multiple comparison test and
indicated with asterisks).
(B) Western blot for LC3 in lysates prepared from 20,000 Flt3 LS cells without or 6-hr post-10-Gy radiation.
(C) Autophagy in HSPCs measured by Cyto-ID staining of autophagic vacuoles. Cells were cultured for 6 hr in the presence or absence of cytokines
(CK represents SCF, Flt3L, IL-11). Fresh cells or starved cells were stained by Cyto-ID.
(D) Quantification of data in (B) (mean ± SD, n = 3 for two experiments; shown is one representative experiment, unpaired two-tailed Student’s t test).D/D HSCs, we treated mice with an inhibitor of phosphatase and
tensin homolog (PTEN), VO-OHpic trihydrate (PTENi). Injection
of PTENi increased p-S6 levels in both f/f and D/D Flt3 LSK
cells, demonstrating that mTOR signaling was activated (Fig-
ure 4D). Activation of mTOR signaling increased the levels of
45S rRNA in both f/f andD/D Flt3 LSK cells (Figure 4E), although
45S rRNA levels were still significantly lower in D/D compared to
f/f cells. Activation of mTOR had no effect on the percentage of
apoptotic f/f or D/D Flt3 LSK cells (Figure 4E), thus increased
mTOR signaling could partially normalize Ribi, but it failed to alter
the low apoptotic phenotype of D/D HSCs.
Increased Autophagy Does Not Contribute to
Decreased Ribi
Autophagy is a process by which cellular contents, including ri-
bosomes, are degraded and recycled for use under starvation
conditions. Lower mTOR signaling can induce autophagy, which
in turn could contribute to the decreased ribosome content of
D/D cells. We analyzed the expression of genes encoding the
core autophagy machinery and several genes whose expression
defines a pro-autophagic signature (Warr et al., 2013) by qPCR.
Expression of the pro-autophagy signature genes was either un-
altered (Bnip3) or slightly lower (Sesn1, Bbc3) in D/D Flt3 LS
cells (Figure 5A). Radiation increased Bbc3 (Puma) mRNA in
both f/f and D/D Flt3 LS cells, but significantly less so in D/D
cells (Figure 5A). The proportion of cleaved versus uncleaved
LC3 protein, which is required for the formation of autophagoso-Cmal membranes, increased to a similar extent in irradiated f/f and
D/D Flt3 LS cells (Figure 5B). We measured autophagy in Flt3
LSK cells and LKS progenitors that were provided or starved for
cytokines by labeling autophagic vacuoles (pre-autophago-
somes, autophagosomes, and autolysosomes) with a cationic
amphiphilic tracer dye, Cyto-ID. Cytokine starvation increased
the staining of autophagic vacuoles in both f/f and D/D Flt3
LSK and LK cells, indicative of increased autophagy (Figures
5C and 5D). However, the autophagic vacuolar staining was
equivalent in D/D and f/f cells in the presence or absence of
cytokines. We conclude that increased autophagy is not the pri-
mary cause of the decreased ribosome content inD/DHSCs and
progenitors. Because mTOR signaling represses autophagy,
and autophagy is not higher in D/D HSCs, this supports our
conclusion that tonic mTOR signaling is not significantly
decreased in D/D HSCs.
Runx1 Directly Regulates Ribi
Because alterations in mTOR signaling and autophagy did not
explain the decreased Ribi, we concluded there was another
explanation, and we examined whether Runx1 directly regulates
Ribi. We analyzed the genome-wide occupancy of RUNX1
using previously published chromatin immunoprecipitation
sequencing (ChIP-seq) data generated in human CD34+ HSPCs
(Beck et al., 2013). We identified 20,552 RUNX1 peaks (q value <
0.01) and examined peaks located within 5 kb of the transcrip-
tional start sites (TSS) of their closest genes (32.37% of allell Stem Cell 17, 165–177, August 6, 2015 ª2015 Elsevier Inc. 171
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Figure 6. Runx1 Is Enriched at the Promoters of Ribosome Protein Genes and Occupies rDNA Repeats
(A) Enrichment of Runx1 binding peaks at the promoters of ribosome protein genes and genes involved in Ribi. Enrichment p value is shown over the bars andwas
computed using hypergeometric distribution. Genes annotated with biological process gene ontology terms related to Ribi plus 80 ribosome protein genes were
analyzed.
(B) qPCR for rRNA and ribosome protein mRNAs in HSPCs (mean ± SD n = 3–5, unpaired two-tailed Student’s t test).
(legend continued on next page)
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RUNX1 peaks); we found that 70.56% of the promoter proximal
regions of 197 genes involved in Ribi, which included 80 genes
encoding large or small ribosome subunit proteins, were occu-
pied by RUNX1 in human CD34+ HSPCs (Figure 6A). Of the
80 genes encoding structural proteins of the ribosome, 65
(80.25%) had a RUNX1 peak within 5 kb of their promoter (Fig-
ure 6A). An additional 45 Ribi genes, including ten ribosome
protein genes, had at least one RUNX1 peak with an enrichment
ofR2-fold over input (Table S1). In comparison, only 29.3%of all
promoters genome-wide were occupied by RUNX1 (Figure 6A).
Therefore RUNX1 binding in human CD34+ HSPCs is highly
enriched at the promoters of Ribi genes (p % 4.1 3 1033),
including the subset of Ribi genes encoding structural compo-
nents of the ribosome (p% 7.63 1022). We performed a similar
analysis of Runx1 occupancy using other published ChIP-seq
datasets, and although the fraction of Ribi genes occupied by
Runx1 was lower in these other cell types and studies, in all
cases occupancy was enriched on Ribi genes (Table S2). We
examined the expression of several ribosome genes occupied
by RUNX1 in more purified populations of mouse HSPCs, and
found significant differences in the levels of Rps3, Rps7, Rpl11,
and rRNA transcripts in both D/D Flt3 LSK and LK(S) cells
when measured on a per-cell basis (Figure 6B). Interestingly,
the expression of Rps7 and 45S rRNA was elevated in D/D
Flt3+ LSK cells (MPPs), and thus the effect of Runx1 loss on
Ribi is context dependent. In conclusion, many genes involved
in Ribi are direct Runx1 targets, and their expression is affected
by an LOF Runx1 mutation.
We next determined whether other hematopoietic transcrip-
tion factors (TFs), including GATA2, FLI1, LYL1, TAL1, LMO2,
and ERG, were enriched on RUNX1-bound promoters in human
CD34+ HSPCs (Beck et al., 2013). We found that FLI1 was highly
enriched on RUNX1-occupied Ribi gene promoters; approxi-
mately 50% of the Ribi gene promoters bound by RUNX1 were
also occupied by FLI1, as compared to 20% of the RUNX1-
bound promoters genome-wide (Figure 6C). GATA2 was also
highly enriched on Ribi gene promoters bound by RUNX1,
although to a lesser extent than FLI1 (Figure 6C). Enrichment
of ERG and LMO2 co-occupancy was significant, whereas co-
occupancy by LYL1 and TAL1 was not enriched.
In addition to occupying the promoters of ribosome protein
genes, all three Runx proteins (Runx1, Runx2, and Runx3)
were previously shown to associate with nucleolar organizing
regions, to bind RUNX consensus sites in the genes encoding
rRNA (rDNA), and to regulate rRNA transcription (Ali et al.,
2008; Young et al., 2007). We analyzed the binding of RUNX1
and the other hematopoietic TFs to the rDNA repeats using the(C) Enrichment of co-occurrence of RUNX1 and other hematopoietic TFs at the
distribution.
(D) TF ChIP-seq peaks across the rDNA sequence. For each TF, the top track sho
called byMACS2. The height of a peak is proportional to the fold enrichment of the
across the rDNA sequence. Binding sites were detected using FIMO at p < 0.00
element; 50-ETS, 50 external spacer; ITS-I/2, internal transcribed spacer regions
(E) Acute deletion of Runx1 in vitro decreases 45S rRNA and translation. Runx1 w
tamoxifen regulated Cre, by addition of 4-OHT to the culture medium. Left: RNA
Right: OP-Puro incorporation (mean ± SD, n = 3; p values determined by unpaire
(F) rRNA levels in primary human AML cells with (MUT) or without (WT) LOF RUN
See also Tables S1 and S2.
Csame ChIP-seq data generated in hCD34+ HSPCs (Beck et al.,
2013). Current genome assemblies do not contain rDNA repeats,
so in order to map ChIP-seq reads to the rDNA sequence we
computationally appended the sequence of a single rDNA repeat
to the proximal tip of chromosome 13 in the human genome
assembly. Because only one rDNA repeat sequence is included
in the assembly, the data obtained represent an aggregate of
signals on all400 rDNA repeats (Zentner et al., 2011). All seven
TFs occupied the upstream control element/core promoter
element (UCE/CPE), and most of the rDNA repeat coding re-
gion, with RUNX1, GATA2, and FLI1 generating the most highly
enriched peaks (Figure 6D). The occupied regions were similar
to those bound by the second largest subunit of DNA polymer-
ase I (RPA116) and the upstream binding protein (UBF) in K562
cells (Zentner et al., 2011). Analysis of the rDNA repeat sequence
identified motifs for the five sequence-specific TFs (RUNX1,
GATA2, FLI1, TAL1, and ERG) throughout the rDNA repeat,
including in the intergenic sequence (IGS) not occupied by any
of the TFs based on the lack of enrichment relative to input
(Figure 6D).
We examined whether acute deletion of Runx1 would
affect the levels of 45S rRNA and translational rate in HSPCs.
Purified HSCs (Flt3 LSK) containing two floxed Runx1 alleles
and a tamoxifen-regulated Cre (Hayashi and McMahon, 2002)
were cultured ex vivo for 48 hr in the presence or absence
of the tamoxifen metabolite 4-hydroxytamoxifen (4-OHT).
The level of 45S rRNA and OP-Puro incorporation were signif-
icantly reduced 48 hr after deletion of Runx1 with Cre + 4-OHT
(Figure 6E), further supporting the hypothesis that Runx1
directly regulates Ribi in HSPCs. We also analyzed the
level of rRNA in primary human AML cells containing LOF
RUNX1 mutations. 18S rRNA was significantly lower in AML
cells containing LOF RUNX1 mutations, suggesting that the
relatively low Ribi phenotype is also a feature of AML blasts
(Figure 6F).
In summary, the Ribi gene promoter and rDNA occupancy
data derived in human CD34+ cells, in addition to the effects of
acute deletion of Runx1 on 45S rRNA levels and translation in
HSPCs, support a direct role for Runx1 in regulating Ribi.
Runx1-Deficient HSPCs Do Not Activate p53
Ribi is the most energy-consuming cellular process, and its
integrity is carefully monitored by a p53 checkpoint. Defects
associated with the ribosomopathies Diamond-Blackfan anemia
(DBA), Schwachman-Diamond syndrome, and in the somatically
acquired 5q syndrome in MDS caused by mutations in Ribi
genes result in activation of p53, G1 growth arrest, and cellularpromoters of Ribi genes. The p values were computed using hypergeometric
ws the normalized ChIP-seq signal and the bottom track shows binding peaks
ChIP-seq signal compared to input control. On the bottom are TF binding sites
5. IGS, intergenic spacer; UCE/CPE, upstream control element/core promoter
1 and 2; Sal box; 30-ETS, 30 external spacer.
as deleted in Runx1f/f cells that were transgenic for a ubiquitously expressed,
levels were measured by qPCR 48 hr after 4-OHT addition (mean ± SD, n = 5).
d two-tailed Student’s t test).
X1 mutations (mean ± SD, n = 5–7, unpaired two-tailed Student’s t test).
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Figure 7. p53 Protein Levels Are Lower in Runx1-Deficient HSPCs
(A) Western blots for p53 in purified HSC and progenitor populations. Lysates from 20,000 cells were loaded in each lane. The p53 and actin blots are different
exposures from the same gel.
(B) p53 in Flt3 LS cells, pre- and 6 hr post-radiation of mice.
(C) qRT-PCR for p53 target genes in Flt3 LS cells, pre- and 6 hr post-radiation or mice (mean ± SEM, n = 3, unpaired two-tailed Student’s t test).
(D) Intracellular p53 staining in HSPCs in the absence or presence of Nutlin-3 treatment in vitro (3 hr at 10 mM). On left are representative histograms for Flt3 LSK
cells. Data for Flt3 LSK and LKS cells are summarized in the bar graph on the right (mean ± SD, n = 5, one-way ANOVA, all values were significantly different
from the comparators [#] by Dunnett’s multiple comparison test).
(E) Annexin V+ Flt3 LS cells in the absence and presence of Nutlin-3 and irradiation in vitro (mean ± SD, n = 5, ANOVA and Dunnett’s multiple comparison tests,
comparator [#]). Significant differences between pairs of samples are indicated by green brackets and determined by unpaired two-tailed Student’s t test.
(F) Annexin V+ Flt3 LSK cells in mice 24 hr post-i.p. injection of Nutlin-3 (20 mg/kg) (mean ± SD, n = 4, unpaired two-tailed Student’s t test).senescence or apoptosis (Golomb et al., 2014). However, we
observed lower p53 protein levels in D/D versus the correspond-
ing f/f populations in western blots of lysates prepared from
equal numbers of HSPCs, including Lineage minus (Lin) and
LKS progenitors, LT-HSCs, and ST- HSCs (Figure 7A). Tp53
mRNA levels were not altered, however, in D/D Flt3 LSK cells
by RNA-seq; therefore, the reduction in p53 protein levels in
LT-HSCs and ST-HSCs occurs post-transcriptionally. The only
population in which p53 was not reduced was CD34+ Flt3+
LSK cells (MPPs) (Figure 7A), which correlated with their normal
size (Figures 2A and 2B), higher levels of 45S rRNA (Figure 6B),
and lack of radiation resistance (Figures 1A and 1B). Radiation
increased p53 levels in f/f Flt3 LS cells, but very little increase
was observed in the equivalent D/D population (Figure 7B).
The activation of several p53 target genes by radiation
(Mdm2, Pmaip1, and Tnip3) was attenuated in D/D Flt3 LS cells
(Figure 7C).
We determined the extent to which activation of p53 could
correct the low apoptotic phenotype of D/D HSCs by treating
cells with the Mdm2-p53 inhibitor Nutlin-3. Treatment with
Nutlin-3 increased the levels of p53 in Flt3 LSK and LKS cells,
although the p53 MFI was lower in D/D cells than in equivalently
treated f/f cells (Figure 7D). Apoptosis was not elevated to the
same extent in D/D Flt3 LS cells as compared to f/f cells in
response to Nutlin 3 treatment in vitro, either in the absence
or presence or radiation (Figure 7E), and Nutlin 3 failed to in-174 Cell Stem Cell 17, 165–177, August 6, 2015 ª2015 Elsevier Inc.crease the percentage of apoptotic D/D Flt3 LSK cells in vivo
when injected into mice (Figure 7F). In summary, we conclude
that the p53 pathway is attenuated in D/D HSPCs, but that
activation of p53 alone cannot reverse the low apoptotic
phenotype.
DISCUSSION
LOF RUNX1 mutations can be early or later events in the pro-
gression of MDS or AML. Here we show that early LOF Runx1
mutations reduce Ribi in HSPCs. The reduction in Ribi correlated
with lower rates of translation and a stress-resistant phenotype,
with attenuated UPR and p53 pathways. The increased stress
resistance resulted in the superior survival of Runx1-deficient
HSCs in the face of genotoxic insults, providing them with a
selective advantage over normal HSCs in the BM. Thus, Runx1
mutations create a ‘‘hibernating’’ pre-LSC that, due to its stress
resistance, can perdure and preferentially accumulate. The
negative impact of Runx1 loss on Ribi could be partially reversed
by activating mTOR signaling, suggesting that one of the impor-
tant contributions of cooperating mutations in AML that activate
signaling pathways may be to at least partially overcome the
decreased Ribi. Importantly, activation of mTOR signaling
increased Ribi without increasing apoptosis, thus the stress
resistance conferred by Runx1 loss persists in the context of pro-
liferative signals, as shown previously for activated Ras signaling
(Motoda et al., 2007). It will be interesting to see if other initiating
mutations in MDS and AML result in dysregulation of Ribi, and
whether this is a common mechanism underlying pre-malig-
nancy. Evaluation of Ribi in human MDS and AML samples will
require normalizing RNA levels based on cell number with
spike-in controls because normalizing by total RNA content will
mask alterations in Ribi (Love´n et al., 2012).
Although we cannot rule out the possibility that altered
expression of cell surface or signaling molecules is responsible
for the decreased Ribi, the ChIP-seq occupancy data suggest
that Runx1 loss directly affects Ribi. The regulation of Ribi by
Runx1 is consistent with previous studies demonstrating that
Runx proteins regulate the transcription of rRNA (Ali et al.,
2008; Young et al., 2007). However, the prior studies showed
that Runx1 functions as a negative regulator of rRNA transcrip-
tion; here we show that Runx1 appears to positively regulate
rRNA transcription in HSCs and progenitors and negatively
regulate it in MPPs. Therefore, the functional outcome of
Runx1 loss is context dependent. The activity of Runx1 in
different contexts may be influenced by cooperating hemato-
poietic TFs such as FLI1, which was previously shown to regu-
late Ribi in Friend erythroleukemic cells (Juban et al., 2009), or
by global regulators of Ribi such as Myc (Dang, 2012). The
chromatin regulatory complexes that Runx1 recruits could
also determine whether the outcome is the activation or repres-
sion of Ribi. For example, Runx1 recruits the polycomb
repressor complex 1 (PRC1) through a direct interaction with
Bmi1 (Yu et al., 2012), and loss of Bmi1 decreased the expres-
sion of multiple Ribi genes in erythroid progenitor cells (Gao
et al., 2015).
The decrease in p53 levels in Runx1-deficient HSPCs is in
direct contrast to the activation of p53 associated with per-
turbed Ribi in the ribosomopathies. Ribosomopathies are
caused by mutations in ribosome proteins or assembly factors
and are thought to create imbalances in ribosome components,
often apparent as an imbalance in the ratio of small and large
ribosome subunits (Teng et al., 2013). This in turn leads to
the accumulation of excess ribosome proteins that cannot be
incorporated into small or large ribosome subunits. Two ribo-
some proteins, RPL5 and RPL11, are major mediators of this
Ribi checkpoint; excess RPL5 and RPL11 bind Mdm2 and
inhibit its interaction with p53, causing p53 to accumulate
(Teng et al., 2013). However, in situations where both rRNA
and mRNAs for ribosome proteins are decreased, p53 levels
tend to be lower rather than higher (Donati et al., 2011). For
example, simultaneous inhibition of rRNA and protein synthesis
by serum starvation or rapamycin treatment was shown to
reduce, rather than increase, p53 levels (Donati et al., 2011).
In Runx1-deficient HSPCs, both rRNA and mRNAs encoding
ribosome proteins were lower, there was no evidence of either
small or large ribosome subunit accumulation, and the p53
checkpoint was not activated.
The demonstration of decreased Ribi and the low metabolic
profile of Runx1-deficient HSPCs raises the issue of how residual
Runx1-deficient leukemic or preleukemic HSCs can be eradi-
cated in patients during or following chemotherapy to reduce
bulk disease. Determining how the survival and stress resistance
of these cells is wiredmay be necessary for devising strategies to
ablate them.CEXPERIMENTAL PROCEDURES
Mice
Runx1f/f;Vav1-Cremice (8–12 weeks old) were described previously (Cai et al.,
2011). Mice were treated according to the University of Pennsylvania’s Animal
Resources Center and IACUC protocols.
Human Samples
AML pheresis and BMmononuclear cells were obtained from the University of
Pennsylvania Stem Cell and Xenograft Core, under the approval from the Uni-
versity of Pennsylvania Institutional Review Board (IRB). All samples lacked
TP53, ATM, KIT, PTEN, JAK2, and KRASmutations. Frozen human AML sam-
ples were recovered in RPMI 1640 with 10% fetal bovine serum, live cells
counted, and RNA prepared from equivalent numbers of cells. FPD/AML sam-
ples were obtained under the approval from the Cincinnati Children’s IRB.
Transplantation
B6.SJL (Ly5.1)micewerepurchased from theNationalCancer Instituteandused
as recipients. Whole BM cells from 129S1/SvImJ (Ly5.2) 3 B6.SJL (Ly5.1) F1
mice (JAX) were used as competitors; 2 3 106 competitor cells mixed with
1.53 106 Runx1f/f or Runx1f/f;Vav1-Cre BM were either irradiated (2 Gy) or not,
and injected into the tail veins of irradiated recipient mice (9 Gy, split dose 3 hr
apart). BM contribution was measured 2 months after transplantation.
Cell Purification and Flow Cytometry
Followed lineage depletion (Miltenyi), BM cells were stained with surface
markers and analyzed/sorted by LSRII/Aria (BD Bioscience). Antibodies are
listed in the Supplemental Experimental Procedures. Dead cells were stained
with 7-AAD (eBioscience) or DAPI (Invitrogen). VO-OHpic (Sigma) was injected
into mice (20 mg/kg i.p.) on 2 consecutive days.
Cell diameters were measured as described elsewhere (Signer et al., 2014).
Intracellular Staining
Cells were fixed by 2% paraformaldehyde, permeabilized by methanol, then
incubated with primary (1:300) and secondary antibody (1:2,000). To measure
translation rates in vivo, mice were injected with OP-Puro (Medchem Source,
50 mg/kg, i.p.), BM was collected 1 hour later and stained for surface markers
and OP-Puro using the Click-iT Protein Synthesis Assay Kit (Life Technologies)
(Signer et al., 2014). To measure translation following Runx1 deletion in vitro,
purified Kit+ cells were cultured with 5 mM4-OHT for 48 hr, andOP-Puro added
20 min before harvesting and staining the cells.
Apoptosis Assays
Micewere killed 24 hr post-radiationwith 3Gy or following a single i.p. injection
with tunicamycin (Sigma, 1 mg/kg) or Nutlin-3 (Sigma, 20 mg/kg), or after the
last of five daily injectionswith AraC (Sigma, 100mg/kg). BM cells were stained
for Annexin V, DAPI, and antibodies against lineage (B220, CD3, Ter119,
Mac1, and Gr1), Sca1, Flt3, CD34, and Kit. Lin cells were enriched with a line-
age depletion kit (Miltenyi), cultured with or without 10 mM Nutlin-3 for 24 hr,
and then stained for cell surface markers.
Autophagy Assay
HSPCs were purified and cultured in Stemspan medium with or without SCF
(150 ng/ml), Flt3 (1 ng/ml), and IL-11 (20 ng/ml) for 6 hr. Cyto-ID staining
was analyzed following the manufacturer’s protocol (Enzo Life Sciences).
Western Blots and qPCR
For this procedure, 23 104 sorted cells were mixed with loading dye and elec-
trophoresed through 4%–12% SDS-PAGE gels for western blots. Total RNA
was extracted with microRNA easy kit (QIAGEN) and digested with DNase
(QIAGEN). Concentration was measured by Bio-analyzer (Agilent). Reverse
transcription and real-time PCRwere performed using standard protocols. An-
tibodies, qPCR primer sequences, and a more detailed western blot protocol
are included in the Supplemental Experimental Procedures.
Polysome Profiling
A total of 4.5 3 106 Lin c-Kit+ cells were sorted and polysome profiling per-
formed using standard protocols.ell Stem Cell 17, 165–177, August 6, 2015 ª2015 Elsevier Inc. 175
Glucose Consumption and ATP Production
Sorted LSK cells were cultured for 24 hr in Stem Span medium. Glucose
concentration in the medium was measured by YSI 7100 Multiparameter
Bioanalytical System (YSI Life Sciences), and ATP in cells using an ATP Detec-
tion Kit (Life Technologies).
ChIP-Seq and RNA-Seq
Methods for ChIP-seq and RNA-seq analysis are described in the Supple-
mental Experimental Procedures.
ACCESSION NUMBERS
The accession number for the RNA-seq data reported in this paper is GEO:
GSE67609.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
one figure, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.stem.2015.06.002.
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